CeQur SA
Simplifying the Life of Diabetes Patients
CeQur has closed its financing round with total funds of USD 115m to advance commercial plans for CeQur Simplicity, its convenient, discreet and 3-day wearable insulin patch for injection-free dosing making insulin always within reach for diabetics. Its commercial plans include market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing.
Dr Andrew Thomas, Managing Partner of Helvetica Capital, says: “The significant medical impact to diabetics through the CeQur Simplicity wearable insulin patch revolutionises regular mealtime insulin delivery. The improved convenience, discreetness and injection-free dosing creates real world benefits to diabetics. We are excited that CSEC has led the financing round with significant participation from new investors, including Tandem Diabetes, Ypsomed Group, and Federated Kaufmann Funds amongst others.”
As part of the investment, Eric Lohrer has joined the Board of Directors on behalf of Credit Suisse Entrepreneur Capital Ltd. Eric will support the board with his broad operational experience gained in various sales and marketing roles at leading healthcare companies in the US, Asia and Europe.
About CeQur
CeQur is commercializing advanced, simple-to-use insulin delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease. The Company’s simple, three-day, wearable devices provide freedom from multiple daily insulin injections.